Pain Affecting Patents (Class 514/18.3)
-
Publication number: 20130137641Abstract: The invention provides agents useful for treating pain. An exemplary agent comprises or consists of the a portion of a retroviral Tat protein. One such agent is the peptide Tat-NR2B9c. This peptide has previously been described as an agent for inhibiting damaging effects of stroke and similar conditions via inhibition of PSD95 interactions with NMDA receptors and/or NOS. The present application provides data showing that the Tat-NR2B9c peptides is effective in alleviation of pain. The alleviation of pain can be obtained at a dose of the peptide below the dose required to inhibit PSD-95 interactions with NMDAR or NOS.Type: ApplicationFiled: November 13, 2012Publication date: May 30, 2013Applicant: NoNO Inc.Inventor: NoNO Inc.
-
Publication number: 20130109614Abstract: Enclosed is an antagonist, which includes a peptide chain represented by an amino acid sequence. The amino acid sequence has a short sequence, C-X1X2X3X4X5-N, which is situated before and neighbored to the third cysteine (Cys, C) of the N-terminus, wherein X1 is an amino acid with aromatic ring, hydrophobic property or long chain, and X2, X3, X4 and X5 are glutamine (G), serine (S), alanine (A) and proline (P) respectively. In one embodiment, X1 is phenylalanine (F). The present antagonists can be used to inhibit or treat with the diseases caused by the activated cells expressing CXCR1 and/or CXCR2 receptor, for example, the acute or chronic inflammatory reaction induced with polymorphonuclear neutrophils (PMNs) expressing CXCR1 and/or CXCR2 receptor, and angiogenesis accompanied by tumor growth inhibition.Type: ApplicationFiled: June 12, 2012Publication date: May 2, 2013Inventors: Jya-Wei Cheng, Kuo-Chun Huang, Hsi-Tsung Cheng, Hui-Yuan Yu
-
Publication number: 20130108602Abstract: Methods of decreasing, reducing, inhibiting, suppressing, limiting or controlling an undesirable or aberrant immune response, immune disorder, inflammatory response, or inflammation in a subject; decreasing, reducing, inhibiting, suppressing, limiting or controlling an autoimmune response, disorder or disease in a subject; and decreasing, reducing, inhibiting, suppressing, limiting or controlling an adverse cardiovascular event or cardiovascular disease in a subject, are provided. Methods include, for example, administering a Nur77 polypeptide or subsequence thereof, a Nur77 agonist, or CD14+ CD16+ monocytes or CD14dimCD16+ (CD115+CD11b+GR1? (Ly6C?)) monocytes or macrophages to a subject to decrease, reduce, inhibit, suppress, limit or control the underlying condition or an adverse symptom or pathology of the condition.Type: ApplicationFiled: October 5, 2012Publication date: May 2, 2013Applicant: LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGYInventor: LA JOLLA INSTITUTE FOR ALLERGY AND IMMU
-
Publication number: 20130096066Abstract: The present invention is direct to a method of producing analgesia in a mammalian subject. The method includes administering to the subject an omega conopeptide, preferably ziconotide, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyil, buprenorphine, and sufentanil, or its pharmaceutically acceptable salts thereof, wherein the ?-conopeptide retains its potency and is physically and chemically compatible with the analgesic compound. A preferred route of administration is intrathecal administration, particularly continuous intrathecal infusion. The present invention is also directed to a pharmaceutical formulation comprising an omega conopeptide, preferably ziconotide, an antioxidant, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyl, buprenorphine, and sufentanil.Type: ApplicationFiled: September 14, 2012Publication date: April 18, 2013Inventors: David J. Ellis, George P. Miljanich, David E. Shields
-
Patent number: 8410054Abstract: The present invention relates to the discovery that mutations in SCN9A are causative of Congenital Indifference to Pain (CIP) in humans. The invention also relates to methods of utilizing the SCN9A gene and expression products thereof for the screening and identification of therapeutic agents, including small organic compounds, which are selective for SCN9A, and are useful in the treatment of pain and other disorders. The invention also relates to methods of using these compounds to treat or otherwise ameliorate such disorders.Type: GrantFiled: November 17, 2009Date of Patent: April 2, 2013Assignee: Xenon Pharmaceuticals Inc.Inventors: Marcia L. MacDonald, Mark E. Samuels, Robin Sherrington, Yigal P. Goldberg
-
Patent number: 8404642Abstract: The present invention relates to the use of Meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain. In a preferred embodiment the disorder to be treated is allodynia, and hyperalgesia, more preferably allodynia including thermal and tactile allodynia.Type: GrantFiled: October 3, 2011Date of Patent: March 26, 2013Assignee: NsGene A/SInventors: Jesper Roland Jørgensen, Lars Ulrik Wahlberg, Teit E. Johansen
-
Patent number: 8399414Abstract: The object of this invention is to provide a novel pharmaceutical composition for getting rid of pains and anxiety in patients. This invention relates to a pharmaceutical composition containing lactoferrin as an active ingredient. The composition of this invention is useful for treatment of at least one disease or condition selected from the group consisting of pains, including the phase 1 pain and the phase 2 pain, anxiety and stress. The composition is particularly beneficial to alleviating or getting rid of the pain and anxiety which significantly lower quality of life of patients with end-stage cancer. The composition of this invention is also useful for treatment of pains, including the phase 1 pain and the phase 2 pain, and inflammation which accompany arthritis or diseases in the junctions of bones (e.g. rheumatoid arthritis, osteoarthritis, frozen shoulder, sports injuries such as tennis elbow and baseball shoulder, and low back pain).Type: GrantFiled: January 17, 2003Date of Patent: March 19, 2013Assignee: NRL Pharma, Inc.Inventors: Etsumori Harada, Takashi Takeuchi, Kenichiro Hayashida, Kunio Ando, Hirohiko Shimizu
-
Patent number: 8399026Abstract: The presently described subject matter relates to isolated spider venom peptides, which are used as potent and selective ion channel blockers, and to a composition and methods for treatment of pain.Type: GrantFiled: September 14, 2010Date of Patent: March 19, 2013Assignee: Alomone Preclinical Ltd.Inventors: Alon Meir, Ronit Simcha Cherki, Ela Kolb, Yael Langut, Nissim Bajayo
-
Patent number: 8394770Abstract: Potassium channels Kv1.3 are known to be implicated in immunological diseases and graft rejections. Disclosed are peptides capable of blocking with high affinity and specificity potassium channels Kv1.3, their pharmaceutical compositions, and methods for their use to block Kv1.3 potassium channels, to treat various immunological conditions and to diagnostic applications. Methods for their chemical synthesis and correct folding are also disclosed. Exemplary peptides correspond to protein components (Vm23 and Vm24) isolated from the venom of the Mexican scorpion Vaejovis mexicanus smithi. Vm23 and Vm24 bind to hKv1.3 channels in an almost irreversible manner, showing a Kd value in the order of 3 picomolar range, when applied to human lymphocytes cultures in vitro. Vm24 was chemically synthesized and used in in vivo experiments to successfully treat sensitized rats (on the DTH-response).Type: GrantFiled: May 14, 2007Date of Patent: March 12, 2013Assignee: Universidad Nacional Autonoma de MexicoInventors: Lourival Domingos Possani-Postay, Georgina Gurrola-Briones, Saida Patricia Salas-Castillo, César Vicente Ferreira Batista, Zoltán S. Varga, György Panyi, Rezsö Gáspár
-
Publication number: 20130053325Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of diseases and disorders such as learning, cognitive activities, and analgesia, particularly in alleviating and/or reducing neuropathic pain.Type: ApplicationFiled: February 11, 2011Publication date: February 28, 2013Inventors: Joseph Moskal, M. Amin Khan
-
Patent number: 8383162Abstract: Methods and compositions for blocking calcium channels with a spider toxin from Phoneutria nigriventer are provided. For easy identification the toxin will be sometimes generally referred to as Ph?-1B herein. The toxin comprises a 55-amino acid sequence having a molecular weight of approximately 6,017. This Ph?-1B spider toxin was found to block calcium channels within the nervous system. The synthetic gene responsible for producing this toxin has been designed and cloned. This gene and/or its derivative provide a mechanism by which the toxin can be produced using recombinant DNA expression technologies. The present invention further relates to methods of treating neurological diseases and pain by applying the isolated and identified toxins. The toxin Ph?-1B may provide beneficial effects on pain and certain neurological conditions including seizures, ischemic- hypoxic, CNS damage, and neurodegenerative disorders. It was also found that the toxins are effective as tags in probing calcium channels.Type: GrantFiled: November 21, 2007Date of Patent: February 26, 2013Assignee: Universidade Federal de Minas GeraisInventors: Marcus Vinícius Gómez, Marco Antônio Máximo Prado, Vânia Ferreira Prado
-
Patent number: 8377479Abstract: Described herein are compositions comprising particles of poorly soluble drugs encapsulated by stabilizers. Further described are pharmaceutical compositions comprising such encapsulated compositions. Also described are methods of making such encapsulated particle compositions, and methods of making the corresponding pharmaceutical compositions. The encapsulated particle compositions described herein allow poorly soluble drugs to be administered with good bioavailability by routes that are non-invasive to patients, such as by oral administration.Type: GrantFiled: September 2, 2008Date of Patent: February 19, 2013Assignee: Nanotherapeutics, Inc.Inventor: James D. Talton
-
Patent number: 8367616Abstract: The invention relates to the use of a granulin or a granulin-like compound for producing a pharmaceutical composition for the therapy or prophylaxis of chronic pain, in particular for neuropathic pain.Type: GrantFiled: July 14, 2008Date of Patent: February 5, 2013Assignee: Johann Wolfgang Goethe-Universitat Frankfurt am MainInventors: Irmgard Tegeder, Gerd Geisslinger
-
Patent number: 8357659Abstract: The invention relates to the use of the peptide toxin APETx2 that blocks the ASIC3 cationic channels and that is derived from the Anthopleura elegantissima sea anemone, and to the use of the analogs and derivatives thereof as a drug, particularly as an analgesic pain associated with the activation of ASIC3 (Acid Sensing Ion Channel 3) channels, in particular pain occurring upon an inflammation and potentially upon any painful situation associated with tissue acidosis (ischemiae, fractures, hematoma, oedema, phlyctena, local infections, tissue lesions, ocular wounds, tumours, etc.).Type: GrantFiled: June 4, 2009Date of Patent: January 22, 2013Assignees: Centre National de la Recherche Scientifique-CNRS, Universite Nice Sophia AntipolisInventors: Emmanuel Deval, Sylvie Diochot, Michel Lazdunski, Eric Lingueglia, Jacques Noel
-
Publication number: 20120329723Abstract: Cell-permeant fusion peptides Tat-PDZ can dose-dependently reduce the threshold for anesthesia. PDZ domain-mediated protein interactions at synapses in the central nervous system play an important role in the molecular mechanisms of anesthesia. Moreover, Tat-PDZ cell-permeant fusion peptides are delivered intracellularly into neurons in the central nervous system subsequent to intraperitoneally injection. By in vitro and in vivo binding assays, we found that the Tat-PDZ dose-dependently inhibited the interactions between NMDARs and PSD-95. Furthermore, behavior testing showed that animals given Tat-PDZ exhibited significantly reduced established inflammatory pain behaviors compared to vehicle-treated group. Our results indicate that by disrupting NMDAR/PSD-95 protein interactions, the Tat-PDZ cell-permeable fusion peptides provide a new approach for inflammatory pain therapy.Type: ApplicationFiled: June 27, 2012Publication date: December 27, 2012Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Roger A. Johns, Feng Tao
-
Publication number: 20120329717Abstract: This invention relates to an isolated, synthetic or recombinant peptide, wherein the peptide comprises the sequence: C K G K G A Xaa1 C R Xaa2 Xaa3 Xaa4 Y Xaa5 C C Xaa6 G Xaa7 C R Xaa8 Xaa9 R C SEQ ID NO: 1 wherein Xaa1, Xaa3, Xaa4, Xaa6, Xaa7 and Xaa8 are independently selected from serine and threonine; Xaa2 is selected from arginine and lysine; Xaa5 is selected from aspartic acid and glutamic acid; and Xaa9 is selected from glycine, alanine, valine, leucine and isoleucine.Type: ApplicationFiled: September 21, 2010Publication date: December 27, 2012Inventors: Richard Lewis, John Adams David, Berecki Geza, Roger Drinkwater, Paul Francis Alewood, James Christie MacDonald
-
Publication number: 20120328635Abstract: The invention relates generally to chaperonin 10 N-terminal variants. More specifically, the invention relates to chaperonin 10 N-terminal variants with enhanced immunomodulatory capacity and/or enhanced binding affinity for pathogen-associated molecular patterns (PAMPs) and/or damage-associated molecular patterns (DAMPs).Type: ApplicationFiled: October 8, 2010Publication date: December 27, 2012Applicant: CBio LimitedInventors: Dean Jason Naylor, Richard James Brown, Christopher Bruce Howard, Christopher John De Bakker, Jeanette Elizabeth Stok, Andrew Leigh James, Daniel Scott Lambert, Kylie Jane Ralston, Walter Rene Antonius Van Heumen, Linda Allison Ward
-
Patent number: 8338641Abstract: The present invention is directed to the use of a class of peptide compounds for treating pain in trigeminal neuralgia.Type: GrantFiled: June 16, 2010Date of Patent: December 25, 2012Assignee: UCB Pharma GmbHInventors: Thomas Stöhr, Christine Rauschkolb-Loeffler
-
Publication number: 20120321612Abstract: Systems, and methods for the use of such systems, are described that allow for the administration of a combination of a sustained release local anesthetic compound (such as bupivicaine) through a catheter based administration device and direct visualization or percutaneous injection of a neurotoxic protein compound (such as botulinum toxin) for post-operative and refractory treated muscle pain and discomfort in patients having undergone spinal surgery and other muscle splitting or treatments aimed at improving muscle pain. The systems utilize specific catheter-based administration protocols and methods for placement of the catheter in association with muscles surrounding the spine and other anatomical sites within the patient. The utilization of an initial bolus of a specific combination of medications (local anesthetic compound and\or neurotoxic protein compound) followed by a dosage pump administration through the catheter is anticipated.Type: ApplicationFiled: August 17, 2012Publication date: December 20, 2012Inventors: Gerardo Zavala, JR., Gerardo Zavala, SR.
-
Publication number: 20120309673Abstract: Compounds of Formula II wherein R1a is H; and R1b is C1-C6alkyl, Carbocyclyl or Het; or R1a and R1b together define a saturated cyclic amine with 3-6 ring atoms; R2a and R2b are independently H, halo, C1-C4alkyl, C1-C4haloalkyl or C1-C4alkoxy, or R2a and R2b together with the carbon atom to which they are attached form a C3-C6cycloalkyl; R3 is a branched C5-C10 alkyl chain, C2-C4haloalkyl or —CH2C3-C7 cycloalkyl; R4? is C1-C6alkyl, C1-C6haloalkyl or oxetany-3-yl. for use in the prophylaxis or treatment of a disorder characterised by inappropriate expression or activation of cathepsin S.Type: ApplicationFiled: December 10, 2010Publication date: December 6, 2012Applicant: Medivir UK LtdInventors: Susana Ayesa, Karolina Ersmark, Urszula Grabowska, Ellen Hewitt, Daniel Jönsson, Pia Kahnberg, Björn Klasson, Peter Lind, Stina Lundgren, Lourdes Odén, Kevin Parkes, Daniel Wiktelius
-
Patent number: 8324168Abstract: The invention provides agents useful for treating pain. An exemplary agent comprises or consists of the a portion of a retroviral Tat protein. One such agent is the peptide Tat-NR2B9c. This peptide has previously been described as an agent for inhibiting damaging effects of stroke and similar conditions via inhibition of PSD95 interactions with NMDA receptors and/or NOS. The present application provides data showing that the Tat-NR2B9c peptides is effective in alleviation of pain. The alleviation of pain can be obtained at a dose of the peptide below the dose required to inhibit PSD-95 interactions with NMDAR or NOS.Type: GrantFiled: September 3, 2009Date of Patent: December 4, 2012Assignee: NoNO Inc.Inventors: Michael P. Belmares, Jonathan David Garman, Peter S. Lu, Michael W. Salter, Michael Tymianski
-
Publication number: 20120295853Abstract: The present invention relates to the discovery of a novel molecular pathway involved in long-term hyperexcitability of sensory neurons, which, in higher animals, is associated with persistent pain. It is based on the discovery that, following injury to an axon of a neuron, an increase in nitric oxide synthase activity results in increased nitric oxide production, which, in turn, activates guanylyl cyclase, thereby increasing levels of cGMP. Increased cGMP results in activation of protein kinase G (“PKG”), which then is retrogradely transported along the axon to the neuron cell body, where it phosphorylates MAPKerk.Type: ApplicationFiled: August 8, 2012Publication date: November 22, 2012Inventors: Richard Ambron, Ying-Ju Sung, Donald W. Landry, Shi-Xian Deng
-
Patent number: 8309088Abstract: Methods are disclosed for treating osteoarthritis in a human subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-human NGF antibody, or antigen-binding fragment thereof, wherein at least one symptom associated with osteoarthritis is prevented, ameliorated or improved.Type: GrantFiled: September 23, 2010Date of Patent: November 13, 2012Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Lynn MacDonald, Richard Torres, Marc R. Morra, Joel H. Martin, Joel C. Reinhardt, Paul Tiseo
-
Publication number: 20120277142Abstract: Provided is a modified human tumor necrosis factor receptor-1 polypeptide or a fragment thereof that binds to a tumor necrosis factor in vivo or ex vivo. The modified human tumor necrosis factor receptor-1 polypeptide or fragment exhibits improved ability to bind tumor necrosis factor and resistance to proteases.Type: ApplicationFiled: December 21, 2011Publication date: November 1, 2012Applicant: HANALL BIOPHARMA CO., LTD.Inventors: Sung Wuk Kim, Sung Soo Jun, Seung Kook Park, Song Young Kim, Eun Sun Kim, Jae Kap Jeong, Ha Na Kim, Yeon Jung Song
-
Patent number: 8288350Abstract: Methods and compositions that can treat a variety of tissue injuries and infections are provided. Tissue-derived leukocyte chemotactic factors are rapidly released after injury to mammalian tissue and can act as the initial signal leading to the initiation and amplification of acute and chronic inflammation associated with injury and infection. The present invention generally provides methods and compositions to prevent and treat injury of cells, tissue, or organs by blocking or inhibiting the release of leukocyte chemotactic factors, by administering certain effective compositions to the tissue.Type: GrantFiled: May 19, 2011Date of Patent: October 16, 2012Assignee: Nour Heart, Inc.Inventors: Salwa A. Elgebaly, Elliott Schiffmann
-
Publication number: 20120245096Abstract: Botulinum toxin, among other presynaptic neurotoxins is used for the treatment and prevention of migraine and other headaches associated with vascular disorders. Presynaptic neurotoxins are delivered focally, targeting the nerve endings of the trigeminal nerve, the occipital nerve and the intranasal terminals of the parasympathetic fibers originating in the Sphenopalatine ganglion. The administration preferably targets the extracranial nerve endings of the trigeminal nerve in the temporal area, the extracranial occipital nerve endings in the occipital area, and the intranasal terminals of the trigeminal nerve and parasympathetic fibers originating in the Sphenopalatine ganglion. The delivery is carried out by way of injection or topically.Type: ApplicationFiled: May 17, 2012Publication date: September 27, 2012Applicant: ALLERGAN, INC.Inventor: Andrew M. Blumenfeld
-
Publication number: 20120232015Abstract: A first aspect of the invention is a compound (sometimes also referred to herein as an “active agent” or “active compound”) of Formula Ia, or more particularly Formula Ib, or a pharmaceutically acceptable salt or prodrug thereof. Compositions thereof and methods of using the same (e.g. for the treatment of a neurological disease) are also described.Type: ApplicationFiled: September 17, 2010Publication date: September 13, 2012Inventors: Harold L. Kohn, Christophe Salomé, Elise Salomé-Grosjean
-
Publication number: 20120220535Abstract: A composition which is reversible inhibitor of at least one neuron-specific PDZ domain comprising wherein R is a molecular transporter with or without a linker amino acid; R1 is at least about one amino acid covalently bound; and, R2 is isoleucine, leucine, alanine, phenylalanine, or valine, and methods of use.Type: ApplicationFiled: May 18, 2010Publication date: August 30, 2012Inventors: Mark Spaller, John Marshall, Dennis J. Goebel
-
Patent number: 8247377Abstract: The present invention provides compounds of formula (I): a process for their preparation, to pharmaceutical compositions comprising the compounds and the preparation of said compositions, to intermediates and to use of the compounds for the manufacture of a medicament for therapeutic treatment, particularly for the treatment of inflammation, allergy and/or autoimmune conditions.Type: GrantFiled: June 11, 2007Date of Patent: August 21, 2012Assignee: Glaxo Group LimitedInventors: Heather Anne Barnett, Ian Baxter Campbell, Diane Mary Coe, Anthony William James Cooper, Graham George Adam Inglis, Haydn Terence Jones, Steven Philip Keeling, Simon John Fawcett MacDonald, Iain McFarlane McLay, Philip Alan Skone, Gordon Gad Weingarten, James Michael Woolven
-
Publication number: 20120208766Abstract: A method for administering an ocular analgesic is described. The method includes the steps of providing a topical analgesic that includes a neo-tryptophan-containing neurotensin analog and applying the topical analgesic to the ocular tissue in a dose of about 0.0001 to about 5 mg, alternatively about 0.0001 to about 3 mg, alternatively about 0.0005 to about 1.2 mg, alternatively about 0.0005 to about 1.0 mg, alternatively about 0.00075 to about 1.0 mg, alternatively about 0.001 mg to about 1.0 mg, alternatively about 0.001 mg to about 0.8 mg, alternatively about 0.001 mg to about 0.7 mg, alternatively about 0.001 mg to about 0.6 mg. Methods of administering a topical analgesic containing a neo-tryptophan-containing neurotensin analog are also described. The topical analgesic can be administered in a patch, gel, lotion, spray, or mist.Type: ApplicationFiled: August 2, 2011Publication date: August 16, 2012Inventors: DENISE BARBUT, Gavril W. Pasternak, Elliott Richelson
-
Publication number: 20120207789Abstract: Ocular analgesics for topical administration are described. The topical ocular analgesic includes a neo-tryptophan-containing neurotensin analog. The topical ocular analgesic may alternatively include a buffered salt solution, a local anesthetic solution, a tissue penetrating agent, and/or an opiate. The neo-tryptophan-containing neurotensin analog may be present in a dose of about 0.0005 to about 1.2 mg.Type: ApplicationFiled: August 3, 2011Publication date: August 16, 2012Inventors: Denise Barbut, Gavril W. Pasternak, Elliott Richelson
-
Publication number: 20120202744Abstract: The present invention relates to the field of anatomy, and more particularly to the control of pain and to the prevention and treatment of osteoarthritic cartilage degradation. Described herein are methods for treating pain which comprise administering to a subject in need a combination of (i) an antagonist of the endothelin type A receptor (ETA) and (ii) an antagonist of the bradykinin B1 receptor (BKB1). Also described are methods for preventing osteoarthritic cartilage degradation and pharmaceutical compositions for treating pain, for preventing osteoarthritic cartilage degradation, and/or for preventing osteoarthritic joint inflammation, in subjects.Type: ApplicationFiled: February 3, 2012Publication date: August 9, 2012Inventors: Florina MOLDOVAN, Gabriel Nathan Kaufman, Pierre Sirois
-
Patent number: 8227416Abstract: Disclosed herein are an agent for treating traumatic peripheral nerve injury comprising a granulocyte colony stimulating factor (G-CSF) as an active ingredient and a method for treating traumatic peripheral nerve injury with the same. The therapeutic agent advantageously regenerates nerve cells and blood vessels in peripheral nerve tissues and thus rehabilitates the injured nerve tissues to improve nerve conduction velocity, and relieves pain induced by traumatic peripheral nerve injury.Type: GrantFiled: March 20, 2009Date of Patent: July 24, 2012Assignee: Industry-University Cooperation Foundation, Hanyang UniversityInventors: Kyung-Soo Kim, Jun-Ho Joe
-
Publication number: 20120183580Abstract: The present invention relates to a pharmaceutical composition comprising a peptide of 5 to 50 amino acids which comprises the amino acid sequence NPFPTX1X2KRX3X4 (SEQ ID NO: 2) wherein X1, X2, X3, and X4 may be the same or different and each is an amino acid residue, wherein said composition is in a form suitable for a transbuccal administration and use thereof for preventing or treating pain.Type: ApplicationFiled: January 13, 2011Publication date: July 19, 2012Applicant: THERALPHAInventor: Michel Lazdunski
-
Publication number: 20120178695Abstract: The disclosure relates, at least in part, to methods of treating neuropathic pain in a patient in need thereof by administering an effective amount of a disclosed compound, e.g. a peptide NMDA receptor partial agonist.Type: ApplicationFiled: July 2, 2010Publication date: July 12, 2012Inventor: Joseph Moskal
-
Patent number: 8217141Abstract: The present invention relates to the crystalline and amorphous structures of SEQ ID NO:1 (FLPS), methods of making the same and use in treatment of various diseases and conditions.Type: GrantFiled: May 19, 2008Date of Patent: July 10, 2012Assignee: Neopro Labs, LLCInventor: Hanna Skubatch
-
Patent number: 8217146Abstract: The invention relates to neublastin neurotrophic factor polypeptides, nucleic acids encoding neublastin polypeptides, and antibodies that bind specifically to neublastin polypeptides, as well as methods of making and methods of using the same.Type: GrantFiled: December 7, 2009Date of Patent: July 10, 2012Assignees: Biogen Idec MA Inc., NsGene A/SInventors: Dinah W. Y. Sah, Teit E. Johansen, Anthony Rossomando
-
Publication number: 20120148604Abstract: The present invention, relates to methods including compounds, derivatives, antibodies, interfering RNA, biologies, polypeptides, dominant negative effectors, and their use in the treatment of neuropathic pain by inhibition of transient receptor potential (TRP) channels. In another embodiment, this invention relates to inhibitors, antagonists, and agonists of TRPC4. TRPC4 therapeutic agents and modulators include but are not limited to small molecule inhibitors, compounds, amino acid derivatives, polypeptides, RNA interference agents, natural chemicals, ligand derivatives, and ions. TRPC4 therapeutic agents and modulators are developed for the treatment of neuropathic pain, including but not limited to pain sensations such as nociception, hyperalgesia, allodynia, and loss of sensory function.Type: ApplicationFiled: August 20, 2010Publication date: June 14, 2012Applicant: TRANSPOSAGEN BIOPHARMACEUTICALS, INC.Inventors: Eric M. Ostertag, John Stuart Crawford
-
Publication number: 20120148583Abstract: A method for delivering a biologic pharmaceutical, comprising: administering an effective amount of a biologic pharmaceutical to a patient in need thereof by perispinal injection, without direct intrathecal or direct epidural injection.Type: ApplicationFiled: February 20, 2012Publication date: June 14, 2012Inventor: Edward L. Tobinick
-
Publication number: 20120142601Abstract: The invention includes compounds that are useful in treating perioperative shivering or temperature spiking, lowering body temperature, treating psychosis or treating pain. The invention also includes methods for treating perioperative shivering or temperature spiking, lowering body temperature, treating psychosis or treating pain in a subject in need thereof.Type: ApplicationFiled: July 20, 2011Publication date: June 7, 2012Inventors: George Walter Koszalka, Justin Orion Brower
-
Publication number: 20120141538Abstract: The present invention concerns modulators of the CX3CR1 receptor. More specifically, antagonists and agonists of the CX3CR1 receptor have been identified. These antagonists and agonists can be used for treating an inflammatory disorder, an autoimmune disorder, a cardiovascular disease, a neurodegenerative disease, a graft versus host disease, a behavioral disorder, a cicatrisation disorder, a viral infection, cancer or pain. They may also be used as an adjuvant in a vaccine composition.Type: ApplicationFiled: December 16, 2009Publication date: June 7, 2012Applicant: UNIVERSITE PIERRE ET MARIE CURIE -PARIS VIInventors: Guy Gorochov, Karim Dorgham, Christophe Combadiere, Philippe Deterre
-
Patent number: 8188048Abstract: The present invention relates generally to methods for inducing, promoting or otherwise facilitating pain relief. More particularly, the present invention relates to a synergistic combination of a selective inhibitor of the neuronal norepinephrine transporter and an analgesic agent in the therapeutic management of vertebrate animals, including humans, for producing analgesia or for the prevention or alleviation of pain.Type: GrantFiled: June 22, 2007Date of Patent: May 29, 2012Assignee: Xenome LimitedInventor: Richard James Lewis
-
Publication number: 20120129784Abstract: Oligopeptides according to formula (I) and/or (II), R1-Tyr-Pro-Trp-Phe-NH2 (I, SEQ ID NO:1); R1-Tyr-Pro-PhePhe-NH2 (II, SEQ ID NO:2), wherein R1 is linked to the NH2-group of the amino-terminal part of Tyr and is selected from the group consisting of —H; a linear saturated or unsaturated or branched saturated or unsaturated acyl group having 1 to 24 carbon atoms, which may be functionalized by a —OH, —SH, —COOH or —CONH+ group; a sterol or a sphingolipid group which is linked to the amino terminal part of Tyr via a bifunctional linker are disclosed. Cosmetic compositions containing the oligopeptides are also disclosed.Type: ApplicationFiled: December 16, 2011Publication date: May 24, 2012Applicant: Cognis IP Management GmbHInventors: Véronique Gillon, Philippe Moussou, Jean-Luc Contet-Audonneau, Olga Freis
-
Publication number: 20120122763Abstract: The present invention provides novel tetrahydrocarbazole compounds according to formula (I) as ligands of G-protein coupled receptors (GPCR) which are useful in the treatment and/or prophylaxis of physiological and/or pathological conditions in mammals mediated by GPCR or of physiological and/or pathological conditions which can be treated by modulation of these receptors.Type: ApplicationFiled: January 25, 2012Publication date: May 17, 2012Applicant: AETERNA ZENTARIS GmbHInventors: Tilmann SCHUSTER, Klaus Paulini, Peter Schmidt, Silke Baasner, Emmanuel Polymeropoulos, Eckhard Guenther, Michael Teifel
-
Publication number: 20120108519Abstract: Methods of inducing antinociception in a human are described. The method includes the step of administering an effective dose of a polypeptide comprising L-neo-tryptophan to the human extracranially. The polypeptide containing L-neo-tryptophan could be, but is not limited to, NT64L, NT65L, NT66L, NT67L, NT69L, NT69L?, NT71, NT72, NT73, NT74, NT75, NT76, or NT77.Type: ApplicationFiled: December 13, 2011Publication date: May 3, 2012Inventors: ELLIOTT RICHELSON, Bernadette Marie Cusack, Yuan-Ping Pang, Daniel J. McCormick, Abdul Fauq, Beth Marie Tyler, Mona Boules
-
Publication number: 20120108518Abstract: The present invention relates to the use of Meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain. In a preferred embodiment the disorder to be treated is allodynia, and hyperalgesia, more preferably allodynia including thermal and tactile allodynia.Type: ApplicationFiled: October 3, 2011Publication date: May 3, 2012Applicant: NsGene A/SInventors: Jesper Roland Jørgensen, Lars Ulrik Wahlberg, Teit E. Johansen
-
Patent number: 8163875Abstract: The following class of molecule is disclosed: a dimer containing a first neublastin polypeptide and a second neublastin polypeptide, wherein: (a) at least one of the polypeptides is glycosylated; (b) at least one of the polypeptides is conjugated at its N-terminus to a water-soluble synthetic polymer; and (c) neither of the polypeptides is conjugated to a water-soluble synthetic polymer at a position other than the N-terminus. Such dimers possess the biological activity of wild-type neublastin while displaying enhanced serum half-life and enhanced potency relative to wild-type neublastin.Type: GrantFiled: April 16, 2004Date of Patent: April 24, 2012Assignee: Biogen Idec MA Inc.Inventors: Dinah Wen-Yee Sah, R. Blake Pepinsky, Anthony Rossomando
-
Publication number: 20120094911Abstract: The present invention provides peptides capable of sustaining antagonist activity against substance P for long periods of time. A peptide selected from (a) to (d) can sustain antagonist activity against substance P, analgesic activity, and anti-inflammation activity for a long period of time: (a)?Ala-Tyr-Gln-Leu-Glu-His-Thr-DTrp-Gln-Gly-Leu- Leu-NH2; (b) a peptide consisting of a partial sequence of (a), which consists of 6 to 11 consecutive amino acids comprising at least the C-terminal Thr-DTrp-Gln-Gly-Leu-Leu-NH2; (c) Ala-Tyr-Gln-Leu-Glu-His-Thr-Phe-Gln-DTrp-Leu-Leu-NH2; and (d) a peptide consisting of a partial sequence of (e), which consists of 6 to 11 consecutive amino acids comprising at least the C-terminal Thr-Phe-Gln-DTrp-Leu-Leu-NH2.Type: ApplicationFiled: May 31, 2010Publication date: April 19, 2012Applicant: UNIVERSITY OF MIYAZAKIInventors: Toshikazu Nishimori, Rumi Naono
-
Patent number: 8158749Abstract: The present invention provides a method for ameliorating inflammatory and/or neuropathic pain in a subject by modifying the activity of N-methyl-D-aspartate (NMDA) receptors in cells of the subject by inhibition of the interaction of the unique domain of the tyrosine kinase Src enzyme and the NMDA receptor complex.Type: GrantFiled: June 21, 2011Date of Patent: April 17, 2012Assignee: The Hospital for Sick ChildrenInventors: Michael W. Salter, Jeffrey R. Gingrich
-
Publication number: 20120087969Abstract: In one embodiment, the present invention relates to novel mu-conotoxin peptides, biologically active fragments thereof, combinations thereof and/or variants thereof. An embodiment of the invention also relates to their use in pharmaceutical composition for the treatment or prevention of pain, and their use in the preparation of an anesthetic.Type: ApplicationFiled: November 8, 2006Publication date: April 12, 2012Applicants: Centre National de la Recherche Scientifique (C.N.R.S.), Atheris LaboratoriesInventors: Philippe Favreau, Evelyne Benoit, Jordi Molgo, Reto Stöcklin